Identification of Immunogenic T and B-Cell Epitope Peptides of Rubella Virus E1 Glycoprotein towards the Development of Highly Specific Immunoassays and Vaccine

Abstract

Introduction: The Rubella virus has a worldwide occurrence and congenital Rubella syndromes are widely recognized as an emerging infection in several parts of the world. Miscarriage, perinatal mortality, and stillbirth can develop in pregnancy during the first trimester. The most frequent techniques for laboratory diagnosis of Rubella virus infection are IgM and IgG-based serological detection methods. Such emerging viral and bacterial pathogen emphasizes the development of fast diagnostic devices; there is a need for enhanced and quicker methods.
 Materials and Methods: Search for peptide vaccine with specific T and B-cell epitopes was identified through bioinformatics-based approaches. These were identified utilizing available Rubella virus E1 glycoprotein sequence databases. The outer-membrane glycoprotein, E1 is a target protein for the prediction of best antigens.
 Results: Using BepiPred2 program, the potential B-cell epitope PFCNTPHGQLEVQVPPDPGD with high conservation among E1 glycoprotein of rubella virus and the maximum surface exposed residues was identified. Using IEDB, NetMHCpan, and NetCTL programs, T-cell epitope RPVALPRAL was identified. Predicted epitopes were found to have promiscuous class-I major histocompatibility complex binding affinity to major histocompatibility complex super types, antigenicity scores, and high proteasomal cleavage. The three-dimensional modeled structures were created using I-TASSER online server for highlighting the predicted T- and B- cell epitopes.
 Conclusion: The predicted T and B cell epitope could be used for the development of immunoglobulin assay and vaccine candidate peptide.